BOCA RATON, Fla., July 19 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) will announce second quarter 2006
financial results on Wednesday, July 26, 2006, after market close. The
company will host a conference call and live webcast at 4:30 p.m. ET.
The live webcast can be accessed at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-
eventDetails&c=100445&eventID=1355022 or via the Nabi Biopharmaceuticals
website at http://www.nabi.com . If you do not have Internet access, the
U.S./Canada call-in number is 866-510-0705 conference code 52609710, and the
international call-in number is 617-597-5363 conference code 52609710. An
audio replay will be available for U.S./Canada callers at 888-286-8010
conference code 61198477, and for international callers at 617-801-6888
conference code 61198477.
An archived version of the webcast will be available at the same
Internet address through August 2, 2006. The audio replay will also be
available through August 2, 2006. The press release will be available on
the company's website at http://www.nabi.com .
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has three products on the market
today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin
(Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi
Biopharmaceuticals is focused on developing products that address unmet
medical needs and offer commercial opportunities in our core business
areas: Gram-positive bacterial infections, hepatitis and transplant, kidney
disease (nephrology) and nicotine addiction. For a complete list of
pipeline products, please go to: http://www.nabi.com/pipeline/index.php .
The company is headquartered in Boca Raton, Florida. For additional
information about Nabi Biopharmaceuticals, please visit our website:
http://www.nabi.com .
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
http://www.nabi.com/pipeline/index.php
CONTACT:
Thomas E. Rathjen, Vice President, Investor
Relations, Nabi Biopharmaceuticals, +1-561-989-5800
|
